- Home
- ROAD vs MIRM Comparison
ROAD vs MIRM Comparison
Compare ROAD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROAD | MIRM |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.2B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ROAD | MIRM |
|---|---|---|
| Price | $82.91 | $80.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $138.14 | ★ $153.07 |
| AVG Volume (30 Days) | 596.0K | ★ 717.1K |
| Earning Date | 11-19-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.46 | ★ 74.59 |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $785,679,000.00 | $19,138,000.00 |
| Revenue This Year | $30.46 | $33.62 |
| Revenue Next Year | $11.82 | $17.72 |
| P/E Ratio | $54.90 | ★ N/A |
| Revenue Growth | ★ 0.31 | N/A |
| 52 Week Low | $79.33 | $63.23 |
| 52 Week High | $151.00 | $130.00 |
Technical Indicators
Market Signals| Indicator | ROAD | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 40.15 |
| Support Level | $79.33 | $78.07 |
| Resistance Level | $95.47 | $88.31 |
| Average True Range (ATR) | 3.32 | 3.96 |
| MACD | 0.25 | 0.58 |
| Stochastic Oscillator | 22.09 | 28.66 |
Price Performance
Historical ComparisonAbout ROAD Construction Partners Inc.
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.